Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toho Aims at Reducing Yakkasa by 1.5-2 Points
June 7, 2010
- Seikagaku: Artz Props Up Sales 1.5% to ¥27,617 Mil.
June 7, 2010
- A Coming of Age
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
June 7, 2010
- Ajinomoto: Pharm. Sales Down 3.7% to ¥82.6 Bil.
June 7, 2010
- Santen: Sales Up 8.8% Driven by Tapros, Hyalein
May 31, 2010
- Sawai: Sales Exceed ¥50.0 Bil. Benchmark
May 31, 2010
- Kyorin: Mainstay Products Drive Sales Up 9.8% to ¥99.8 Bil.
May 31, 2010
- Towa: Strong Growth in Sales to Pharmacies Drive Business
May 31, 2010
- Kaken: Sales Up 2.5% to ¥85 Bil. Driven by Artz
May 31, 2010
- Nippon Chemiphar: Sales, Profits Up Driven by Generics
May 31, 2010
- Mochida: Sales Up 4.5% to ¥78.5 Bil. Driven by Epadel
May 31, 2010
- Rufinamide to Enter PIII in Japan: Eisai
May 31, 2010
- Nippon Shinyaku: Pharm. Sales Up 3.6% Driven by Mainstay Products
May 31, 2010
- Bayer Initiates PIII of Regorafenib in mCRC
May 31, 2010
- Kissei: Sales Down 3.7%, Off-Patent Products Struggle
May 31, 2010
- Sosei Initiates PIII for QVA149
May 31, 2010
- Medipal: Sales Up 3.3% to ¥2,546 Bil.
May 31, 2010
- 9-Valent HPV Vaccine under Development in Japan: Banyu
May 31, 2010
- Fully Explain Characteristics of Asthma to Patients to Improve Compliance: Prof. Ohta
May 31, 2010
- Alfresa HD: Sales Up 6.4% to ¥2,059.2 Bil.
May 31, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…